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Research Gi- and Gq-coupled ADP (P2Y) receptors act in 
opposition to modulate nociceptive signaling and 
inflammatory pain behavior
Sacha A Malin and Derek C Molliver*
Abstract
Background: Investigations of nucleotide signaling in nociception to date have focused on actions of adenosine 
triphosphate (ATP). Both ATP-gated ion channels (P2X receptors) and G protein-coupled (P2Y) receptors contribute to 
nociceptive signaling in peripheral sensory neurons. In addition, several studies have implicated the Gq-coupled 
adenosine diphosphate (ADP) receptor P2Y1 in sensory transduction. In this study, we examined the expression and 
function of P2Y1 and the Gi-coupled receptors P2Y12, P2Y13 and P2Y14 in sensory neurons to determine their 
contribution to nociception.
Results: We detected mRNA and protein for ADP receptors P2Y12 and P2Y13 in mouse dorsal root ganglia (DRG). 
P2Y14, a homologous Gi-coupled nucleotide receptor, is also expressed in DRG. Immunohistochemical analysis of 
receptor distribution indicated that these receptors are widely expressed in nociceptive neurons. Using ratiometric 
calcium imaging, we found that ADP evokes increases in intracellular calcium in isolated DRG neurons and also 
produces a pertussis toxin-sensitive inhibition of depolarization-evoked calcium transients. The inhibitory effect of ADP 
was unaltered in the presence of the selective P2Y1 antagonist MRS2179 and in neurons isolated from P2Y1 knockout 
mice, whereas ADP-evoked calcium transients were greatly reduced. Analysis of behavioral responses to noxious heat 
before and after inflammatory injury (injection of complete Freund's adjuvant into the hindpaw) revealed that P2Y1 is 
required for the full expression of inflammatory hyperalgesia, whereas local injection of agonists for Gi-coupled P2Y 
receptors reduced hyperalgesia.
Conclusions: We report that Gi-coupled P2Y receptors are widely expressed in peripheral sensory neurons. Agonists 
for these receptors inhibit nociceptive signaling in isolated neurons and reduce behavioral hyperalgesia in vivo. Anti-
nociceptive actions of these receptors appear to be antagonized by the Gq-coupled ADP receptor, P2Y1, which is 
required for the full expression of inflammatory hyperalgesia. We propose that nociceptor sensitivity is modulated by 
the integration of nucleotide signaling through Gq- and Gi-coupled P2Y receptors, and this balance is altered in 
response to inflammatory injury. Taken together, our data suggest that Gi-coupled P2Y receptors are broadly expressed 
in nociceptors, inhibit nociceptive signaling in vivo, and represent potential targets for the development of novel 
analgesic drugs.
Background
Adenosine triphosphate (ATP) has been studied for more
than 30 years as a potential nociceptive messenger [1].
Extensive investigation into the role of purinergic signal-
ing in nociception was stimulated by the identification of
ATP-gated ion channels (the P2X receptors) in primary
afferent nociceptors. More recently, several groups have
implicated members of the P2Y family of G protein-cou-
pled nucleotide receptors in sensory transduction [2,3].
In contrast to the ATP-selective (purinergic) P2X recep-
tors, the 8 known P2Y receptors respond to a variety of
purine and pyrimidine nucleotides (Table 1). In sensory
neurons, activation of the Gq-coupled receptor P2Y2 by
ATP and/or UTP causes the release of intracellular cal-
cium stores, action potential firing, the release of neuro-
peptides and activation of the transcription factor CREB
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([4-6]). The ADP receptor P2Y1 is also expressed in sen-
sory neurons and has been implicated in sensory trans-
duction [7,8]. Evidence for the expression and function of
other P2Y receptors in sensory neurons is limited [2,9].
The recently-identified P2Y receptors P2Y12, P2Y13
and P2Y14 represent a subfamily of nucleotide GPCRs
with only limited homology to the Gq-coupled P2Y
receptors and distinct signal transduction mechanisms
via Gi/o [10]. For convenience, these three receptors will
be collectively referred to here as P2YGi receptors. P2Y12
and P2Y13 are preferentially activated by ADP, whereas
P2Y14 is selective for glycosylated UDP. Although these
compounds are metabolites of ATP and UTP and thus
present in the sensory neuron milieu, the extent to which
these receptors and their ligands contribute to sensory
signal transduction remains under active investigation.
Activation of Gi-coupled receptors in sensory neurons is
often associated with inhibition of N-type Ca++ channels
and attenuation of neurotransmitter release, which is the
principle mechanism for the inhibition of peripheral
nociceptive signaling by mu opioid receptor agonists
[11,12]. This phenomenon has been demonstrated using
fura-2 Ca++ imaging to visualize the inhibition of depolar-
ization-evoked Ca++ influx by opioid agonists in dissoci-
ated DRG neurons [13,14]. Here, we demonstrate that
P2Y12, P2Y13 and P2Y14 are all expressed in sensory
neurons of the dorsal root ganglia (DRG) with neuro-
chemical characteristics of nociceptors. Ligands for each
of these receptors inhibit depolarization-evoked influx of
extracellular Ca++. Expression of all three Gi-coupled
nucleotide receptors is regulated in response to inflam-
mation, indicating that changes in P2YGi expression con-
tribute to the neuronal response to inflammatory injury.
Results described here indicate that ADP acts at both the
Gq-coupled P2Y1 and the Gi-coupled P2Y12 and P2Y13
receptors in sensory neurons, and suggest that the inte-
gration of these antagonistic pathways is an important
mechanism for the modulation of nociceptor sensitivity.
Results
Expression of mRNA for all three of the Gi-coupled P2Y
receptors was identified in mouse lumbar DRG by real-
t i m e  P C R ,  w i t h  r e l a t i v e  l e v e l s  o f  e x p r e s s i o n  o f  P 2 Y 1 2
~P2Y14 > P2Y13 (Table 1). To determine whether expres-
sion is altered in response to inflammatory injury, 20 μl
complete Freund's adjuvant (CFA) was injected into the
plantar surface of the hindpaw, and real-time PCR was
used to quantify changes in mRNA abundance compared
to uninjected baseline levels (Figure 1). The three P2YGi
receptors were coordinately regulated: expression was
initially reduced one day after CFA injection, but signifi-
cantly upregulated at day 4. Expression of P2YGi receptor
mRNA returned to baseline by day 15, by which time
behavioral response thresholds to noxious heat had also
returned to baseline levels.
Immunohistochemistry for all three P2YGi  receptors
revealed intense staining in the great majority of small-
diameter neurons, consistent with widespread expression
Table 1: P2Y receptors and nucleotide agonists.
Receptor Signaling Preferred Agonist ΔCT (DRG)
P2Y1* Gq/11 ADP 6.22 ± 0.11
P2Y2* Gq/11 ATP = UTP 6.17 ± 0.08
P2Y4*‡ Gq/11 ATP = UTP 13.63 ± 0.31
P2Y6* Gq/11 UDP 10.92 ± 0.14
P2Y12 Gi/o ADP 7.55 ± 0.26
P2Y13** Gi/o ADP = IDP 9.78 ± 0.59
P2Y14 Gi/o Glycosylated UDP 7.91 ± 0.59
Relative expression levels of mRNA for P2Y family members in DRG are expressed as the normalized cycle threshold (ΔCT): the P2Y CT value 
minus the CT for the reference standard, GAPDH. *Previously published data [28]. ‡Rodent P2Y4 receptor shows equivalent responsiveness to 
ATP and UTP; the human receptor is selective for UTP. **Mouse but not human P2Y13 shows high affinity for IDP as well as ADP. P2Y11 is not 
included here because it is not expressed in rodents. (See [10,37-39]).Malin and Molliver Molecular Pain 2010, 6:21
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in nociceptors (Figure 2). Although P2Y12 immunoreac-
tivity was restricted to small neurons, both P2Y13 and
P2Y14 were detected in some larger neurons. Staining
was less intense in large neurons. Consistent with this
observation, only 4.2 ± 2.0% of P2Y12-positive neurons
were positive for neurofilament, a marker for neurons
with myelinated axons [15], while 17.5 ± 4.3% of P2Y13-
positive and 29.5 ± 5.1% of P2Y14-positive neurons dis-
played immunoreactivity for neurofilament (Figure 2).
As is evident in Table 1, P2 receptors have a high degree
of agonist promiscuity, which has hindered analysis of
receptor-specific effects. To determine whether P2YGi
receptors are capable of modulating depolarization-
evoked Ca++ transients, we used ratiometric Ca++ imaging
to measure responses to a combination of agonists and
antagonists in neurons isolated from wildtype and P2Y1-/
- mice. Both P2Y12 and P2Y13 are activated by ADP [16],
but, P2Y13 is the only P2Y receptor with high affinity for
IDP. P2Y14 is unique in that it is highly selective for gly-
cosylated UDP [10]. Therefore, we compared the actions
of ADP, IDP and UDP-glucose (UDPG) on isolated mouse
DRG neurons. Because ADP is also an agonist for the Gq-
coupled P2Y1 receptor, we characterized agonist effects
in neurons from both wildtype and P2Y1-/- mice.
Application of ADP (100 μM) to isolated wildtype DRG
neurons evoked a transient increase in intracellular Ca++
in roughly half of all neurons, consistent with the activa-
tion of Gq-coupled signaling (Table 2). This proportion
dropped to less than 10% of neurons in the presence of
the selective P2Y1 antagonist MRS2179, and of neurons
isolated from P2Y1-/- mice. These data indicate that
most ADP responses in vitro were mediated by P2Y1.
When the concentration of ADP was reduced to 10 μM,
the percentage of responsive neurons dropped to 35%;
the magnitude of responses also decreased, indicating
submaximal activation of P2Y1 signaling. These results
support the functional expression of P2Y1 in approxi-
mately 40% of DRG neurons in vitro.
To examine the actions of the P2YGi receptors, we first
tested the ability of ADP to inhibit Ca++ transients evoked
by a depolarizing stimulus of 50 mM K+. ADP (100 μM)
inhibited both the magnitude and the duration of depo-
larization-evoked transients in the majority of neurons in
vitro (Figure 3A). ADP was equally effective in neurons
Figure 1 P2YGi receptor mRNA levels are regulated in response to inflammatory injury. A) Amplification of DRG cDNA by conventional RT-PCR 
using the P2YGi real-time PCR primers produced a single band for each receptor of the expected size (100-150 bp). B) Real-time PCR was used to an-
alyze mRNA levels for each of the Gi-coupled P2Y receptors and the Gq-coupled P2Y1 at 1, 4 and 15 days after induction of inflammatory hyperalgesia 
by injection of complete Freund's adjuvant into the hindpaw. The shaded box indicates the period of significant heat hyperalgesia determined using 
the Hargreaves test. Data are normalized against baseline values. *p < 0.01, ‡p < 0.05, For PCR, n = 5 mice/time point. For behavior, n = 10 mice/time 
point.Malin and Molliver Molecular Pain 2010, 6:21
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Figure 2 P2YGi receptor immunoreactivity is localized in sensory neurons of the DRG. Staining for P2Y12 (A), P2Y13 (B) and P2Y14 (C) in cryostat 
sections of DRG neurons double-labeled for the high-molecular weight neurofilament protein, NFH, used as a marker of neurons with myelinated ax-
ons. Antibodies for all three receptors intensely stain small-diameter, NFH-negative neurons. However, P2Y12 expression is largely restricted to NFH-
negative neurons, whereas P2Y13 and P2Y14 are expressed in some NFH-positive sensory neurons (arrowheads). n = 3 mice, > 400 cells/antibody.Malin and Molliver Molecular Pain 2010, 6:21
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from P2Y1-/- mice, ruling out an essential role for P2Y1
(Figure 3B). The inhibitory effect of ADP was lost when
cells were pretreated overnight with 250 nM pertussis
toxin, indicating that inhibition was mediated through a
Gi-coupled pathway (n = 3 mice, 32 cells, data not
shown). IDP and UDPG also inhibited depolarization-
evoked Ca++ transients (Figure 3C-D; Table 3).
Neurons inhibited by nucleotides were tested for
responsiveness to 1 μM capsaicin to test for expression of
the capsaicin receptor TRPV1 as a marker for a subset of
nociceptors [17]. A large proportion of capsaicin-respon-
sive neurons was inhibited by nucleotides, consistent
with our hypothesis that P2YGi receptors have inhibitory
actions in nociceptive sensory neurons (Table 3). UDPG
inhibited the largest proportion of capsaicin-responsive
neurons, followed by ADP and IDP. Application of ADP,
IDP or UDPG resulted in long-lasting inhibition in many
cells. Responses at 5, 10 and 15 minutes post-agonist
application were compared to peak responses to depolar-
izing stimuli obtained prior to P2YGi receptor activation;
these data are shown in Figure 4. This reduction in
response magnitude does not reflect run-down, as cells
not treated with nucleotides showed no diminution of
depolarizing responses. These data suggest that P2YGi
activation may have analgesic effects in vivo.
Surprisingly, the inhibitory effects of nucleotides on
sensory neuron function were enhanced by the blockade
of P2Y1. Application of MRS2179 increased both the
magnitude and duration of ADP-evoked inhibition of
depolarizing responses (Figure 4). Similar results were
obtained from P2Y1-/- neurons (Figure 3, 4). This finding
suggests that P2Y1 signaling antagonizes the action of
P2YGi receptors.
Our analysis of nucleotide signaling in isolated neurons
suggests that P2YGi receptors have inhibitory actions in
sensory neurons, whereas P2Y1 is excitatory. To deter-
mine the impact of these receptors on nociceptive signal-
ing in vivo, we examined the effects of P2Y agonists on
behavioral responses to noxious heat using the Har-
greaves test in naïve mice and after inducing inflamma-
tion by injecting complete Freund's adjuvant (CFA) into
the plantar surface of the hindpaw. Baseline paw with-
drawal latencies were not different between wildtype and
P2Y1-/- mice (Figure 5A), and both wildtype and mutant
mice developed persistent thermal hyperalgesia after
CFA injection. However, mutant mice were significantly
less sensitized than wildtype at the peak of hyperalgesia
on day 3, suggesting that the sensitization of nociceptors
by inflammatory injury is modestly impaired in the
absence of P2Y1 signaling.
We next examined the acute effect of exogenous ADP
on heat sensitivity. ADP injection into the hindpaw (10
nmol/10 μl) did not cause acute nocifensive behavior,
consistent with a previous report [18]. However, ADP
Table 2: ADP evokes Ca++ transients through P2Y1.
10 μM ADP 100 μM ADP MRS2179
100 μM ADP
wildtype
% responders 35 ± 5% 52 ± 6% 8 ± 3%
n (cells) 37 197 40
wildtype
response size (ΔF) 0.09 ± 0.01 0.53 ± 0.05 0.18 ± 0.02
wildtype
response area (ΔFarea) 1 ± 2 11 ± 2 6 ± 1
P2Y1-/-
% responders ND 9 ± 4% 10 ± 1%
n (cells) 100 55
P2Y1-/-
response size (ΔF) ND 0.90 ± 0.28 1.31 ± 0.32
P2Y1-/-
response area (ΔFarea) ND 15 ± 3 18 ± 4
Dramatically fewer sensory P2Y1-/- neurons produce ADP-evoked calcium transients compared to wildtype neurons. Remaining responses 
in P2Y1-/- neurons are similar in size to those seen in wildtype. Similar effects were obtained using MRS2179, a P2Y1-specific antagonist. 
Frequency and response magnitude values are mean ± SEM.Malin and Molliver Molecular Pain 2010, 6:21
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caused a sustained decrease in withdrawal latencies to
noxious heat (heat hyperalgesia) in wildtype mice that
lasted up to 48 hours (Figure 5B). No hyperalgesia
occurred in P2Y1-/- mice, indicating that the hyperalge-
sia was likely mediated by P2Y1. Strikingly, significant
hypoalgesia was seen after ADP injection in P2Y1-/-
mice, suggesting an antinociceptive action of other ADP
receptors that was occluded in the presence of P2Y1.
To further explore the contribution of P2Y1 to inflam-
matory hyperalgesia, either ADP or a selective P2Y1
antagonist was injected into the inflamed pa w of mice
three days after CFA injection (Figure 5C-D). The P2Y1
antagonist MRS2500 (1.5 nmol/10 μl) caused a significant
reduction in hyperalgesia evident at 30 and 60 minutes.
ADP injection (10 nmol/10 μl) into the hindpaw 3 days
after CFA did not alter hyperalgesia in inflamed wildtype
mice, but caused a complete reversal of hyperalgesia in
P2Y1-/- mice that lasted at least 4 hours. These results
are consistent with the in vitro data indicating an anti-
nociceptive action of ADP that was masked or antago-
nized in the presence of P2Y1.
Finally, P2YGi agonist IDP (P2Y13) or UDPG (P2Y14)
(each at 10 nmol/10 μl) was injected into the hindpaws of
wildtype mice at CFA day three. Both agonists caused
temporary but complete reversal of CFA-evoked hyperal-
gesia lasting at least 60 minutes (Figure 5E-F). UDPG
caused significant hypoalgesia at 30 and 60 minutes post-
injection (mice were less sensitive to noxious heat than at
baseline). This antinociceptive effect was still significant
24 hours after injection. The high efficacy of UDPG in
behavioral experiments correlates well with our Ca++
imaging results: UDPG showed the greatest amount of
inhibition and the largest proportion of capsaicin-
responsive neurons inhibited in vitro.
Discussion
The identification of nucleotide receptors in nociceptive
sensory neurons has spurred investigation of the mecha-
nisms by which nucleotides contribute to nociceptive
transmission. We provide evidence that P2Y1 has pro-
nociceptive actions in sensory neurons and participates
in inflammatory sensitization. Furthermore, we demon-
strate that Gi-coupled P2Y receptors are expressed in
sensory neurons, are dynamically upregulated in
response to inflammation and inhibit excitatory signaling
in sensory neurons, including capsaicin-responsive noci-
ceptors.
Our results conflict with a previous report analyzing
P2Y12 and P2Y14 mRNA by in situ hybridization in rat
DRG, which concluded that radiographic silver grains
observed were not localized to neuronal cell bodies [9].
Here, we used real-time PCR, immunohistochemistry
and functional analysis of agonist responses using Ca++
imaging and behavioral assays to document the expres-
sion of P2YGi receptors in sensory neurons from mouse
D R G .  A n t i b o d i e s  t o  e a c h  o f  t h e  r e c e p t o r s  r e v e a l e d
intense neuronal labeling. All three receptors showed
particularly intense labeling in small-diameter neurons,
which comprise the majority of nociceptors. This inter-
pretation is supported by the demonstration of P2YGi
agonist-evoked inhibition of Ca++ transients in many cap-
saicin-responsive (and thus presumably nociceptive) sen-
sory neurons. Less-intense P2Y13 and P2Y14
immunoreactivity in larger neurons suggests that these
receptors may contribute to functional properties of large
A-fiber nociceptors and/or some non-nociceptive neu-
rons. Finally, ganglionic mRNA levels of all three recep-
tors were coordinately regulated in response to hindpaw
injection of CFA, indicating that modulation of Gi-cou-
pled nucleotide receptor signaling is part of the neuronal
response to inflammatory injury.
Gi-coupled receptors, including opioid receptors,
inhibit sensory transmission by blocking voltage-gated
Ca++ channels (VDCCs) that regulate neurotransmitter
release both peripherally and centrally. Inhibition of
depolarization-evoked Ca++ influx by opioid agonists in
sensory neurons has been demonstrated previously using
Ca++ imaging [13,14]. This most likely occurs through a
direct interaction of the G protein βγ subunit and the
VDCCs (Herlitze et al., 1996; Ikeda, 1996; Zamponi and
Snutch, 1998). We used a similar protocol to demonstrate
the ability of nucleotide agonists for P2Y12, P2Y13 and
P2Y14 to inhibit Ca++ transients in DRG neurons from
both wildtype and P2Y1-/- mice. Similarly, previous stud-
ies have demonstrated inhibition of VDCCs and neu-
rotransmitter release by P2Y12 and/or P2Y13 in PC12
cells and sympathetic neurons [19-21].
Gerevich et al [22] reported that P2Y1 mediates inhibi-
tion of VDCCs in isolated DRG neurons by ADP through
an action of the βγ subunits of Gq. Intriguingly, these
authors also demonstrated that intrathecal administra-
tion of a non-selective agonist of P2Y1, P2Y12 and P2Y13
(ADP-β-S) inhibited spinal nociceptive transmission and
nocifensive behavior in the rat tail flick test [22]. Our
results in P2Y1-/- mice demonstrate that P2Y1 is not nec-
essary for the inhibition of Ca++ signaling by ADP. Indeed,
the inhibitory action of ADP in isolated neurons and on
pain behavior in vivo was enhanced in the absence of
P2Y1 signaling, suggesting an action of P2Y12 and/or
P2Y13. However, our results suggest that the dominant
e ff ect  of  ADP  i n wi ldt ype m ic e  is  p r o-nocic ept i ve a nd
that this action requires P2Y1. Application of ADP to
DRG neurons in vitro evoked increases in intracellular
Ca++, and subcutaneous injection of ADP in wildtype
mice caused heat hyperalgesia, a finding consistent with a
previous report that an ADP analog enhanced heat
responses in isolated polymodal nociceptors [23]. In theMalin and Molliver Molecular Pain 2010, 6:21
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absence of P2Y1, ADP was anti-nociceptive, suggesting
an action of P2YGi receptors that is normally occluded by
P2Y1. Such interactions between Gq and Gi signaling do
not appear to be unique to P2Y receptors, as a previous
study found that genetic deletion of the Gq effector phos-
pholipase C beta 3 resulted in enhanced Gi signaling
through the mu opioid receptor [24].
The expression of ADP receptors in sensory neurons, in
addition to ATP-gated P2Y receptors and P2X channels,
begs the question of how these diverse extracellular sig-
nals are integrated in the neuron. While much work
remains to be done on this issue, one key factor is the reg-
ulation of local nucleotide concentration by extracellular
nucleotidases. Most nucleotidases rapidly degrade micro-
molar ATP but degrade ADP more slowly, resulting in the
rapid termination of ATP signaling and a more persistent
ADP signal; relative kinetics depend on which family
members are expressed [25]. Tonic or spontaneous
release of ATP might thus result in little or no ATP sig-
naling, but tonic ADP signaling (for example, see [26]).
Table 3: Extent of inhibition by P2YGi receptor agonists.
Agonist (genotype) ADP (wt) IDP (wt) UDPG (wt) ADP (P2Y1-/-)
All DRG
Inhibition frequency 65 ± 7% 73 ± 4% 66 ± 10% 75 ± 7%
Inhibition magnitude 48 ± 5% 33 ± 4% 38 ± 4% 44 ± 4%
n(cells) 185 48 120 112
TRPV1+ DRG
Inhibition frequency 59 ± 9% 88 ± 13% 82 ± 8% 61 ± 14%
Inhibition magnitude 34 ± 22% 31 ± 6% 56 ± 10% 47 ± 9%
n ( c e l l s ) 1 1 2 3 07 07 2
P2YGi receptor agonists inhibit depolarization-evoked Ca++ transients in sensory neurons at 5 minutes after application. Table shows the 
percentage of sensory neurons in wild type and P2Y1-/- mice inhibited by each agonist and the magnitude of inhibition (change in peak 
response); values are given as mean ± SEM. Data are given for all sensory neurons, as well as for capsaicin-responsive cells (TRPV1+).
Figure 3 P2YGi agonists inhibit depolarization-evoked increases in intracellular Ca++. Fura-2 Ca++ imaging was used to measure the effect of 
P2Y receptor agonists on Ca++ transients evoked by administration of 50 mM K+. Application of ADP (100 μM) for 3 minutes reduced subsequent de-
polarization-evoked transients in wildtype (A) and P2Y1-/- (B) mice. The P2Y13 agonist IDP (C) and the P2Y14 agonist UDPG (D) also inhibited depo-
larization-evoked transients.Malin and Molliver Molecular Pain 2010, 6:21
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Acute release of ATP caused, for instance, by tissue dam-
age, rapidly activates P2X receptors, which rapidly desen-
sitize [27]. G protein signaling is generally more delayed
and prolonged and modulates physiological properties of
the neurons. As an example, onset of UTP (P2Y2)-evoked
action potentials in vitro took tens of seconds and was far
m o r e  p e r s i s t e n t  t h a n  P 2 X - e v o k e d  f i r i n g  [ 4 ] .  A  s i m i l a r
time course was seen for ADP-evoked (P2Y1) Ca++ tran-
sients, which in vivo requires hydrolysis of the ATP signal
before activation ([28]; this study). Thus, ATP signaling is
likely to be more acute, whereas ADP signaling is likely to
be more delayed and prolonged.
Our results indicate that P2YGi  receptors negatively
regulate the sensitivity of peripheral nociceptive sensory
neurons. Given these findings, we were surprised to find
that the widely-prescribed anti-thrombotic drug clopi-
dogrel (Plavix), a P2Y12 antagonist, is used extensively in
humans with extremely limited reports of pain-related
contraindications. It is possible that extensive co-expres-
sion of P2Y12 with P2Y13 in sensory neurons, both of
which are Gi/o-coupled ADP receptors, prevents pro-
nociceptive consequences of peripheral P2Y12 antago-
nism in experimental models and in patients using clopi-
dogrel. Furthermore, there is evidence that P2Y12 is
required for the expression of neuropathic pain due to a
key role in the activation of spinal microglia after nerve
injury [29,30]. Because of the powerful actions of spinal
microglia in neuropathic pain models, systemic blockade
of P2Y12 appears to be protective against persistent pain
at the spinal level despite the anti-nociceptive actions of
this receptor in primary afferents. Further studies will be
required to determine whether P2Y12 antagonism is del-
eterious in models of persistent pain that lack a signifi-
cant contribution from microglia.
Opioid receptors are the most extensively studied Gi-
coupled receptors in sensory neurons due to their potent
anti-nociceptive actions. Interestingly, the pattern of reg-
ulation of the P2YGi receptor mRNAs in response to CFA
Figure 4 The inhibitory effect of ADP is enhanced in the absence of P2Y1 signaling. The magnitudes of depolarization-evoked Ca++ transients 
in sensory neurons were measured before, and 5, 10 and 15 minutes after agonist application. Ca++ transients were not affected by application of buf-
fer alone (dashed lines), but were significantly reduced after application of ADP (A-B), IDP (C), or UDPG (D; solid lines). Inhibition was prolonged by 
application of the selective P2Y1 antagonist MRS2179 (A) and in neurons from P2Y1-/- mice (B). There was no effect of MRS2179 in P2Y1-/- neurons 
(B). Values are mean ± SEM; n = 10 mice/timepoint each treatment. *p < 0.02 versus control for each treatment.Malin and Molliver Molecular Pain 2010, 6:21
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Figure 5 ADP has opposing effects on behavioral nociceptive thresholds in the presence and absence of P2Y1. ADP has opposite effects on 
withdrawal latencies to noxious heat stimuli (Hargreaves test) in the presence and absence of P2Y1. A) P2Y1-/- mice show a deficit in thermal hyper-
algesia at day 3 following CFA injection, compared to wildtype mice. B) Injection of ADP into the hindpaw of naïve mice caused thermal hyperalgesia 
in wildtype mice, but hypoalgesia in P2Y1-/- mice. C) Mice were injected with ADP in the hindpaw three days after CFA injection and thermal response 
thresholds were measured. ADP injection had no effect on thermal thresholds in inflamed wildtype mice, but reversed thermal hyperalgesia in P2Y1-
/- mice. D) Hindpaw injection of MRS2500, a P2Y1 antagonist, in inflamed wildtype mice acutely reversed thermal hyperalgesia compared to saline 
injection. Injection of either IDP (E) or UDPG (F) into the inflamed hindpaw reversed inflammation-evoked thermal hyperalgesia. n = 10 mice/cohort.Malin and Molliver Molecular Pain 2010, 6:21
http://www.molecularpain.com/content/6/1/21
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was grossly similar to regulation of mRNA for the mu
opioid receptor [31]. Opiates are generally effective in
treating inflammatory pain, however they have poten-
tially dangerous side effects, including tolerance and sup-
pression of respiration and gastrointestinal motility.
Several studies indicate that in the peripheral nervous
system, opioid receptors are preferentially expressed in
peptidergic nociceptors, identified by expression of the
neuropeptide CGRP. Wu and colleagues found that both
opioid receptor immunoreactivity and opioid inhibition
of VDCCs were significantly greater in IB4-negative (pre-
sumptive peptidergic) neurons than in IB4-positive neu-
rons, indicating preferential expression of opioid
receptors in the peptidergic nociceptors [32]. We found
immunoreactivity for P2Y12, P2Y13 and P2Y14 in virtu-
ally all small neurons. Inhibitory signaling through P2YGi
receptors is thus likely to impact nociceptive signaling in
both peptidergic and non-peptidergic nociceptors.
Therefore, it may be possible to improve the treatment of
persistent pain by targeting P2YGi receptors, either alone
or in combination with opiates; such combination ther-
apy may allow the use of lower doses (and reduced side-
effects) than would be possible when targeting a single
receptor.
Conclusions
We describe functional effects of Gi-coupled P2Y recep-
tors in sensory neurons and implicate these receptors in
the regulation of nociceptive signaling. P2YGi receptors
are widely expressed in sensory neurons and inhibit noci-
ceptive signaling. We also found that inflammatory hype-
ralgesia is reduced in the absence of functional P2Y1. We
propose that pro- and anti-nociceptive nucleotide recep-
tors are broadly co-expressed by nociceptive sensory neu-
rons, and that the integration of these opposing signals
adjusts nociceptor sensitivity. These signaling pathways
are transcriptionally regulated in response to inflamma-
tory injury.
Methods
Mice
Adult male wild type C57/Bl6 mice or P2Y1 null mutant
mice bred onto the C57Bl6 background were used for all
experiments. P2Y1 knockout mice (generously provided
by Dr. Beverly Koller, University of North Carolina, Cha-
pel Hill) were maintained as homozygotes and bred nor-
mally [33]. All mice were housed in group cages,
maintained on a 12:12 hour light-dark cycle in a tempera-
ture controlled environment (20.5°C) and given food and
water ad libitum. These studies were carried out in accor-
dance with the guidelines of the Institutional Animal
Care and Use Committee at the University of Pittsburgh
and the NIH Guide for the Care and Use of Laboratory
Animals.
Real-Time PCR
Real-time PCR analysis was carried out as previously
described [31]. Briefly, L3, L4 and L5 dorsal root ganglia
were dissected bilaterally and collected on dry ice. To iso-
late RNA, frozen tissue samples were placed in 1 ml Tri-
zol reagent (Invitrogen, Carlsbad, CA), homogenized,
extracted in chloroform and separated in phase lock gel
tubes (Eppendorf, Hamburg, Germany). RNA was precip-
itated in isopropanol at -20°C for 1 hour then on dry ice
for 1 hour, then washed with 75% ethanol and resus-
pended in water. RNA quality was determined using an
Agilent (Palo Alto, CA) 2100 Bioanalyzer according to the
manufacturer's instructions and quantity was determined
using the 260 nm absorbance recorded by a spectropho-
tometer. Extracted RNA was treated with DNase (Invitro-
g e n )  t o  r e m o v e  g e n o m i c  D N A  ( 1  μ l  D N a s e ,  2  μ l  1 0 ×
DNase buffer, 0.25 μl RNasin/5 μg RNA in H2O, 20 μl
total/reaction). RNA was then reverse-transcribed using
Invitrogen Superscript II reverse transcriptase according
to the manufacturer's instructions. Negative control reac-
tions were run without RNA to test for contamination.
PCR primers were generated using Primer Express soft-
ware (Applied Biosystems, Foster City, CA) with parame-
ters optimized by the manufacturer. SYBR Green PCR
amplification was performed using an Applied Biosys-
tems 5700 real-time thermal cycler controlled by a Dell
Latitude laptop computer running ABI Prism 7000 SDS
software. After amplification, a dissociation curve was
plotted against melting temperature to ensure amplifica-
tion of a single product. All samples were run in tripli-
cate, and reactions were run without template and with
the reverse-transcriptase negative control reaction prod-
ucts as negative controls with every amplification run.
Threshold cycle (Ct) values, the cycle number in which
SYBR Green fluorescence rises above background, are
recorded as a measure of initial template concentration.
Relative fold changes in RNA levels were calculated by
the ΔΔCt method using p53-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as a reference standard: Ct val-
ues from samples run in triplicate (n = 5 mice/time point,
not pooled) were averaged and subtracted from the refer-
ence standard, yielding ΔCt. The difference between the
ΔCt of the experimental and control groups was then cal-
culated (ΔΔCt). The relative fold change was determined
as 2-ΔΔCt. Statistical significance was determined by
ANOVA using the Statview software package. Data were
plotted as the percent change in mRNA levels compared
to baseline.
Inflammation
An emulsion of CFA (heat-killed and dried Mycobacte-
rium tuberculosis in paraffin oil and mannide
monooleate; Sigma, St. Louis, MO) was prepared by thor-
oughly mixing equal volumes of sterile saline and CFA.Malin and Molliver Molecular Pain 2010, 6:21
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Mice received a sub-cutaneous injection of the CFA
emulsion (20 μl) in the plantar surface of both hindpaws
[34]. Animals were deeply anesthetized with Avertin in
saline and killed by transcardial perfusion with 4°C iso-
tonic saline at 1, 4 or 15 days after CFA injection.
Behavioral Analysis
Mice (n = 10/genotype) were placed in individual plexi-
glass chambers on a glass plate maintained at 30°C and
allowed to acclimate for one hour. In all behavioral exper-
iments, the experimenters were blinded to the genotype
of the mice and any drug treatment. Paw withdrawal
latencies to noxious heat stimulation were measured by
applying a radiant heat stimulus (15% intensity on the
Hargreaves apparatus; IITC Inc.) to each hindpaw. The
heat source was activated with an electric trigger coupled
to a timer, and the latency to stimulus response (flinching
or lifting the paw) was recorded to the nearest 0.1 second.
Nucleotides and P2Y antagonists were purchased from
Sigma (IDP) or Tocris.
Immunohistochemistry
Mice were given an overdose of Avertin anesthetic and
killed by transcardial perfusion with 4°C saline followed
by 4% paraformaldehyde. DRGs were rapidly dissected,
placed in 25% sucrose overnight and frozen in OCT
mounting medium. Cell counts were performed in lum-
bar L4 DRG. Sections were cut at 12 microns on a cry-
ostat and collected on Superfrost microscope slides, then
kept at -20°C until used. Slides were placed in blocking
solution containing 2% normal donkey serum, 0.2% Tri-
ton X-100 in PBS for 30 minutes, then incubated in pri-
mary antibody solution overnight at room temperature.
Next, slides were washed 3 times for 3 minutes in PBS
and incubated for 30 minutes in secondary antibodies
diluted 1:500 in blocking solution. Secondary antibodies
w e r e  d o n k e y  a n t i - r a b b i t  o r  d o n k e y  a n t i - m o u s e  c o n j u -
gated to CY3 or CY2 (Jackson Immunoresearch, West
Grove PA). Slides were washed 3 times in PBS, dipped in
water and coverslipped in glycerol-based fluorescent
mounting medium (Dako), then photographed under epi-
fluorescence with a digital camera. Primary antibodies
used were rabbit polyclonal anti-P2Y1 (Alomone), anti-
P2Y12 (Alomone; 1:200), anti-P2Y13 (Novus; 1:300) and
anti-P2Y14 (Affinity Bioreagents; 1:2000). To test for
selectivity, sections were processed with antibodies
adsorbed against the antigenic peptide, and with second-
ary antibody alone. No staining was seen in the absence
of primary antibody, and preadsorbtion with antigenic
peptide abolished staining. Antigenic peptide was not
available for P2Y14.
Calcium Imaging
Isolated neurons were prepared as described [35]. Adult
mice were given an overdose of Avertin anesthetic and
perfused transcardially with 4°C Ca++/Mg++-free Hank's
basic salt solution (HBSS). All cervical, thoracic and lum-
bar DRGs were rapidly dissected and cleaned in HBSS.
Ca++ imaging was performed 18-24 hours after plating
essentially as previously described [36]. Cells were loaded
with 2 mM fura-2-AM in HBSS with 5 mg/ml bovine
serum albumin for 30 minutes at 37°C, then mounted on
a microscope stage with constantly flowing HBSS at 5 ml/
minute. Perfusion rate was controlled with a gravity flow
system and perfusate temperature was maintained at
30°C using heated stage and in-line heating system (War-
ner Instruments). Drugs were delivered with a computer-
controlled rapid-switching local perfusion system.
Firmly-attached, refractile cells were identified as regions
of interest in the software (Simple PCI, C-Imaging).
Absorbance data at 340 and 380 nm were collected once
per second and the relative fluorescence (ratio 340/380)
was plotted against time. Calcium transients were exam-
ined in response to application of agonists as noted in the
figure legends. Calcium responses were quantified as the
percentage of cells responding to a given agonist and the
amplitude, area, latency and duration of the response
using Excel macros written for this purpose.
To evaluate the inhibition of evoked transients by
P2Y12, P2Y13 and P2Y14, a 5 second application of 50
mM K+ in HBSS was applied twice with a 5 minute inter-
val to verify reproducible calcium transients, then the
appropriate agonist was perfused for 3 minutes before
and during the 3rd depolarization. Successive applications
of 50 mM K+ were delivered at 5 minute intervals to
determine the duration of inhibition. In some experi-
ments, 1 μM capsaicin was applied to determine inhibi-
tion in capsaicin-responsive nociceptors. Capsaicin was
dissolved in 1-methyl-2-pyrrolidinone as a 10 mM stock
solution; 1 μM capsaicin was made fresh daily in HBSS.
Pertussis toxin (250 nM; Tocris) was applied to cultures
overnight.
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